These 12 Fortune 500 companies have survived wars, crashes, and over 200 years of U.S. history

The article highlights the longevity of several Fortune 500 companies, including Molson Coors, BNY, State Street, Cigna, and other long-lived financial and insurance institutions. Molson Coors is cited at No. 390 on the Fortune 500 with $11.14 billion in revenue and more than 16,000 employees, but the piece is primarily a historical and strategic profile rather than new operating news. Overall market impact is limited.

Analysis

The relevant signal here is not age, but survivorship bias in regulated, capital-intensive franchises: banks and insurers can compound for centuries because their moats are reinforced by regulation, inertia, and customer switching costs. That tends to favor the largest incumbents in periods of market stress, because franchise value and deposit/asset stickiness become more important than near-term growth, especially when funding markets tighten. For that reason, the article is mildly supportive of JPM and STT on a multi-quarter basis, but the bigger implication is that durability itself becomes a valuation premium only when balance-sheet discipline is credible.

The second-order effect is that longevity narratives can mask strategic stagnation. Institutions that survive for 200 years do so by avoiding existential mistakes, not by maximizing optionality, so they often underperform in late-cycle risk-on rallies when investors pay up for faster-moving financials or asset-sensitive names. In other words, the market may be over-allocating to the "quality lasts forever" story while missing that these businesses are still exposed to fee compression, technology disintermediation, and regulatory capital drag over a 12-36 month horizon.

For CI, the key is that durability in healthcare services does not automatically translate into multiple expansion; it mostly lowers terminal-risk discounting. If the market starts rewarding perceived stability in managed care and health services, the cleaner expression may be through relative value rather than outright long exposure. TAP.A is effectively irrelevant to the thesis, which itself is informative: legacy alone is not enough to attract capital without a visible earnings or capital-return catalyst.

Contrarian take: the consensus may be too quick to equate centuries of existence with current investability. The same traits that preserve firms over generations can also suppress near-term upside because they prioritize resilience over growth. The tradeable edge is to own the names where longevity is paired with an active catalyst, and fade the ones where the story is purely historical branding.

Key Decisions for Investors

• Long JPM vs. short KRE for the next 3-6 months: prefer the systemically important bank with explicit risk discipline over regional banks if macro volatility rises; target 8-12% relative outperformance if credit headlines re-accelerate.
• Pair long CI / short XLV for 2-4 quarters: use CI as the lower-beta defensive compounder while shorting the broad sector to isolate relative stability; upside is modest but drawdown should be limited if healthcare multiples compress.
• Buy STT on pullbacks only, then sell upside calls 1-2 quarters out: the stock can rerate on capital-market stability, but durability is already partially priced, so cap the upside and harvest theta.
• Avoid initiating a standalone long in legacy-brand names without a catalyst; if forced, express via a basket long of JPM and CI against a short of slower-growth financial/healthcare peers to reduce factor noise.
• Use TAP.A as a no-trade/underweight signal in the consumer staples complex: historical brand equity without a clear earnings inflection is unlikely to outperform over the next 6-12 months.